GeneDx (NASDAQ:WGS) Sees Large Volume Increase - Should You Buy?

Key Points

• Q1 earnings miss and guidance cut: GeneDx reported EPS of ($0.28) vs. ($0.06) expected and revenue of $102.25M vs. $112.46M expected, then cut FY‑2026 revenue guidance to ~$475–490M (vs. ~549M consensus), triggering a sharp post‑earnings selloff and a volume spike to 1,230,294 shares (+40%).
• Rising legal and financial risk: Multiple securities‑fraud investigations, a large operating loss, meaningful cash burn and recent insider selling increase liability and liquidity concerns that could sustain selling pressure.
• Divergent market views: Despite the selloff, most analysts still rate the stock a Buy (average target ~$96.43), and notable insider moves include Director Keith Meister's large purchase even as the CFO sold shares to cover tax obligations.

Shares of GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) saw an uptick in trading volume on Wednesday . 1,230,294 shares changed hands during mid-day trading, an increase of 40% from the previous session's volume of 881,302 shares.The stock last traded at $35.7850 and had previously closed at $34.51.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Revenue and gross profit rose year‑over‑year in Q1 (growth vs. prior year), showing underlying demand even as margins and mix deteriorated. QuiverQuant Q1 recap
• Neutral Sentiment: Some sell‑side firms trimmed price targets but retained “buy” ratings (Guggenheim, BTIG), indicating continued bull case among certain analysts despite the reset. BTIG price target note
• Negative Sentiment: Q1 results missed consensus — EPS and revenue were well below expectations — and management cut FY‑2026 revenue guidance to ~$475–490M (vs. ~549M consensus), citing lower blended reimbursement rates and weaker non‑core lines. That guidance reset triggered the initial selloff. MarketBeat Q1/guidance release
• Negative Sentiment: Multiple law firms have launched securities‑fraud investigations and shareholder solicitations (Block & Leviton, Holzer & Holzer, Glancy Prongay, Frank R. Cruz, Ademi, Johnson Fistel), increasing legal and liability risk and likely adding selling pressure. Block & Leviton alert
• Negative Sentiment: Market reaction: shares plunged (intraday post‑earnings) and trading volume spiked well above average — a sign of forced or panic selling and heightened volatility. Media coverage highlighted the “alarming” miss and guidance shift. AP: shares plummet
• Negative Sentiment: Financial stress signals in filings/coverage: a large reported operating loss, meaningful cash burn in the quarter, and significant recent insider selling noted by data providers — items that can pressure sentiment until visibility improves. QuiverQuant financial details & insider activity

Wall Street Analyst Weigh In

Several brokerages recently issued reports on WGS. Craig Hallum reiterated a "buy" rating and issued a $85.00 price target on shares of GeneDx in a research note on Tuesday. Canaccord Genuity Group set a $75.00 price target on shares of GeneDx and gave the stock a "buy" rating in a research note on Tuesday. Guggenheim decreased their price target on shares of GeneDx from $100.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday. BTIG Research decreased their price target on shares of GeneDx from $170.00 to $90.00 and set a "buy" rating for the company in a research note on Tuesday. Finally, Jefferies Financial Group set a $150.00 price objective on GeneDx in a research report on Monday, February 23rd. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, GeneDx has an average rating of "Moderate Buy" and an average target price of $96.43.

GeneDx Stock Performance

The firm has a market capitalization of $1.02 billion, a P/E ratio of -12.95 and a beta of 2.06. The company has a current ratio of 2.46, a quick ratio of 2.34 and a debt-to-equity ratio of 0.16. The business's 50 day simple moving average is $70.50 and its two-hundred day simple moving average is $106.59.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.22). The firm had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 8.85%. During the same quarter in the prior year, the business posted ($0.23) earnings per share. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.75 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Kevin Feeley sold 392 shares of the company's stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total transaction of $25,554.48. Following the transaction, the chief financial officer directly owned 34,942 shares of the company's stock, valued at $2,277,868.98. This represents a 1.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Keith A. Meister purchased 140,026 shares of the company's stock in a transaction dated Thursday, March 5th. The shares were bought at an average cost of $81.19 per share, for a total transaction of $11,368,710.94. Following the acquisition, the director owned 3,228,150 shares in the company, valued at approximately $262,093,498.50. The trade was a 4.53% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders sold 104,028 shares of company stock valued at $7,377,165. Corporate insiders own 29.60% of the company's stock.

Hedge Funds Weigh In On GeneDx

Several hedge funds and other institutional investors have recently modified their holdings of the company. Jones Financial Companies Lllp boosted its stake in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock worth $25,000 after buying an additional 186 shares during the last quarter. Kestra Advisory Services LLC purchased a new position in shares of GeneDx in the 4th quarter worth $27,000. Fifth Third Bancorp purchased a new position in shares of GeneDx in the 1st quarter worth $31,000. Quarry LP boosted its holdings in shares of GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company's stock worth $32,000 after buying an additional 209 shares during the last quarter. Finally, Ramirez Asset Management Inc. purchased a new position in shares of GeneDx in the fourth quarter worth approximately $33,000. 61.72% of the stock is owned by institutional investors.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.